Get the Stockscreener App
35.47
0.37%
-0.13
After Hours:
35.46
-0.010
-0.03%
Royalty Pharma Plc stock is traded at $35.47, with a volume of 2.30M.
It is down -0.37% in the last 24 hours and up +2.63% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$35.60
Open:
$35.41
24h Volume:
2.30M
Relative Volume:
0.58
Market Cap:
$14.95B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
15.14
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
-1.80%
1M Performance:
+2.63%
6M Performance:
+15.35%
1Y Performance:
+26.23%
1-Day Range:
$35.24
$35.79
1-Week Range:
$35.24
$36.89
52-Week Range:
$24.05
$36.89
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.47 | 15.22B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Victory Capital Management Inc. Grows Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com South Africa
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times
Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative
Royalty Pharma adds two independent directors to board - StreetInsider
Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan
Strata Wealth Advisors LLC Invests $387,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Cerity Partners LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Royalty Pharma Q2 2025 Earnings Call: Key Details for August 6 Pre-Market Release - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighHere's Why - MarketBeat
Why Royalty Pharma plc stock attracts strong analyst attentionDaily Swing Candidates - Newser
How Royalty Pharma plc stock performs during market volatilityMarket Timing Advice - beatles.ru
What makes Royalty Pharma plc stock price move sharplyFree Trading Group - Newser
M&T Bank Corp Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Bank of New York Mellon Corp Has $45.53 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
D.A. Davidson & CO. Trims Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Rehmann Capital Advisory Group Purchases New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 36.44 USD By Investing.com - Investing.com South Africa
Royalty Pharma PLC (NASDAQ:RPRX) Stake Lessened by China Universal Asset Management Co. Ltd. - MarketBeat
Royalty Pharma stock hits 52-week high at 36.44 USD - Investing.com
Royalty Pharma PLC (NASDAQ:RPRX) Stock Holdings Boosted by Amalgamated Bank - Defense World
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Vontobel Holding Ltd. - Defense World
Sumitomo Mitsui DS Asset Management Company Ltd Acquires 13,615 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
(RPRX) Trading Report - news.stocktradersdaily.com
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price - simplywall.st
Wealth Enhancement Advisory Services LLC Has $509,000 Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Royalty Pharma PLC (NASDAQ:RPRX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
New South Capital Management Inc. Sells 49,656 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Downgraded by Wall Street Zen to Hold - MarketBeat
Royalty Pharma stock hits 52-week high at $36.32 By Investing.com - Investing.com Nigeria
Royalty Pharma stock hits 52-week high at $36.32 - Investing.com
Royalty Pharma plc(NasdaqGS: RPRX) dropped from Russell 1000 Defensive Index - MarketScreener
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Paragon Capital Management Inc. - MarketBeat
Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year - Yahoo
Robeco Institutional Asset Management B.V. Grows Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
(RPRX) Investment Report - news.stocktradersdaily.com
Is Royalty Pharma Plc technically bullish or bearish? - MarketsMojo
Royalty Pharma Announces $2 Billion Funding Arrangement with Revolution Medicines for Daraxonrasib Development - Nasdaq
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds - Benzinga
Royalty Pharma stock hits 52-week high at $35.41 By Investing.com - Investing.com India
Advisor Resource Council Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Yousif Capital Management LLC Purchases New Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Assenagon Asset Management S.A. - Defense World
SG Americas Securities LLC Invests $1.67 Million in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock? - simplywall.st
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Bank Pictet & Cie Europe AG - MarketBeat
Wealth Enhancement Advisory Services LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Wealth Enhancement Advisory Services LLC Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Trading Signals - news.stocktradersdaily.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):